Literature DB >> 1401067

Degradation of endogenous bacterial cell wall polymers by the muralytic enzyme mutanolysin prevents hepatobiliary injury in genetically susceptible rats with experimental intestinal bacterial overgrowth.

S N Lichtman1, E E Okoruwa, J Keku, J H Schwab, R B Sartor.   

Abstract

Jejunal self-filling blind loops with subsequent small bowel bacterial overgrowth (SBBO) induce hepatobiliary injury in genetically susceptible Lewis rats. Lesions consist of portal tract inflammation, bile duct proliferation, and destruction. To determine the pathogenesis of SBBO-induced hepatobiliary injury, we treated Lewis rats with SBBO by using several agents with different mechanisms of activity. Buffer treatment, ursodeoxycholic acid, prednisone, methotrexate, and cyclosporin A failed to prevent SBBO-induced injury as demonstrated by increased plasma aspartate aminotransferase (AST) and elevated histology scores. However, hepatic injury was prevented by mutanolysin, a muralytic enzyme whose only known activity is to split the beta 1-4 N-acetylmuramyl-N-acetylglucosamine linkage of peptidoglycan-polysaccharide (PG-PS), a bacterial cell wall polymer with potent inflammatory and immunoregulatory properties. Mutanolysin therapy started on the day blind loops were surgically created and continued for 8 wk significantly diminished AST (101 +/- 37 U/liter) and liver histology scores (2.2 +/- 2.7) compared to buffer-treated rats (228 +/- 146 U/liter, P < 0.05, 8.2 +/- 1.9, P < 0.001 respectively). Mutanolysin treatment started during the early phase of hepatic injury, 16-21 d after surgery, decreased AST in 7 of 11 rats from 142 +/- 80 to 103 +/- 24 U/liter contrasted to increased AST in 9 of 11 buffer-treated rats from 108 +/- 52 to 247 +/- 142 U/liter, P < 0.05. Mutanolysin did not change total bacterial numbers within the loop, eliminate Bacteroides sp., have in vitro antibiotic effects, or diminish mucosal PG-PS transport. However, mutanolysin treatment prevented elevation of plasma anti-PG antibodies and tumor necrosis factor-alpha (TNF alpha) levels which occurred in buffer treated rats with SBBO and decreased TNF alpha production in isolated Kupffer cells stimulated in vitro with PG-PS. Based on the preventive and therapeutic activity of this highly specific muralytic enzyme, we conclude that systemic uptake of PG-PS derived from endogenous enteric bacteria contributes to hepatobiliary injury induced by SBBO in susceptible rat strains.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1401067      PMCID: PMC443175          DOI: 10.1172/JCI115996

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  31 in total

1.  Measurement of bacterial cell wall in tissues by solid-phase radioimmunoassay: correlation of distribution and persistence with experimental arthritis in rats.

Authors:  R Eisenberg; A Fox; J J Greenblatt; S K Anderle; W J Cromartie; J H Schwab
Journal:  Infect Immun       Date:  1982-10       Impact factor: 3.441

2.  The relation of experimental arthritis to the distribution of streptococcal cell wall fragments.

Authors:  F G Dalldorf; W J Cromartie; S K Anderle; R L Clark; J H Schwab
Journal:  Am J Pathol       Date:  1980-08       Impact factor: 4.307

3.  Measurement of streptococcal cell wall in tissues of rats resistant or susceptible to cell wall-induced chronic erosive arthritis.

Authors:  S K Anderle; J B Allen; R L Wilder; R A Eisenberg; W J Cromartie; J H Schwab
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

4.  Effect of acetylation on arthropathic activity of group A streptococcal peptidoglycan-polysaccharide fragments.

Authors:  S A Stimpson; R A Lerch; D R Cleland; D P Yarnall; R L Clark; W J Cromartie; J H Schwab
Journal:  Infect Immun       Date:  1987-01       Impact factor: 3.441

5.  In vivo degradation of bacterial cell wall by the muralytic enzyme mutanolysin.

Authors:  M J Janusz; R E Esser; J H Schwab
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

6.  Comparison of in vivo degradation of 125I-labeled peptidoglycan-polysaccharide fragments from group A and group D streptococci.

Authors:  S A Stimpson; R E Esser; W J Cromartie; J H Schwab
Journal:  Infect Immun       Date:  1986-05       Impact factor: 3.441

7.  Arthropathic properties of cell wall polymers from normal flora bacteria.

Authors:  S A Stimpson; R R Brown; S K Anderle; D G Klapper; R L Clark; W J Cromartie; J H Schwab
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

8.  Granulomatous enterocolitis induced in rats by purified bacterial cell wall fragments.

Authors:  R B Sartor; W J Cromartie; D W Powell; J H Schwab
Journal:  Gastroenterology       Date:  1985-09       Impact factor: 22.682

9.  Promotion of the translocation of enteric bacteria from the gastrointestinal tracts of mice by oral treatment with penicillin, clindamycin, or metronidazole.

Authors:  R D Berg
Journal:  Infect Immun       Date:  1981-09       Impact factor: 3.441

10.  Treatment of experimental erosive arthritis in rats by injection of the muralytic enzyme mutanolysin.

Authors:  M J Janusz; C Chetty; R A Eisenberg; W J Cromartie; J H Schwab
Journal:  J Exp Med       Date:  1984-11-01       Impact factor: 14.307

View more
  24 in total

Review 1.  Hepatobiliary abnormalities and parenteral nutrition.

Authors:  B S Tomar
Journal:  Indian J Pediatr       Date:  2000-09       Impact factor: 1.967

2.  Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis.

Authors:  David N Abarbanel; Scott M Seki; Yinka Davies; Natalie Marlen; Joseph A Benavides; Kathleen Cox; Kari C Nadeau; Kenneth L Cox
Journal:  J Clin Immunol       Date:  2012-10-09       Impact factor: 8.317

3.  Normal luminal bacteria, especially Bacteroides species, mediate chronic colitis, gastritis, and arthritis in HLA-B27/human beta2 microglobulin transgenic rats.

Authors:  H C Rath; H H Herfarth; J S Ikeda; W B Grenther; T E Hamm; E Balish; J D Taurog; R E Hammer; K H Wilson; R B Sartor
Journal:  J Clin Invest       Date:  1996-08-15       Impact factor: 14.808

Review 4.  Primary sclerosing cholangitis.

Authors:  Y Ueno; N F LaRusso
Journal:  J Gastroenterol       Date:  1994-08       Impact factor: 7.527

5.  High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis.

Authors:  Jean-Marc Sabaté; Pauline Jouët; Florence Harnois; Charlotte Mechler; Simon Msika; Maggy Grossin; Benoît Coffin
Journal:  Obes Surg       Date:  2008-02-20       Impact factor: 4.129

Review 6.  Phlogistic properties of peptidoglycan-polysaccharide polymers from cell walls of pathogenic and normal-flora bacteria which colonize humans.

Authors:  J H Schwab
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

7.  Bacterial cell wall polymers (peptidoglycan-polysaccharide) cause reactivation of arthritis.

Authors:  S N Lichtman; S Bachmann; S R Munoz; J H Schwab; D E Bender; R B Sartor; J J Lemasters
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

Review 8.  Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies.

Authors:  James H Tabibian; Steven P O'Hara; Keith D Lindor
Journal:  Scand J Gastroenterol       Date:  2014-07-03       Impact factor: 2.423

Review 9.  Atypical p-ANCA in PSC and AIH: a hint toward a "leaky gut"?

Authors:  Birgit Terjung; Ulrich Spengler
Journal:  Clin Rev Allergy Immunol       Date:  2009-02       Impact factor: 8.667

Review 10.  The immunobiology of primary sclerosing cholangitis.

Authors:  Jonathan H Aron; Christopher L Bowlus
Journal:  Semin Immunopathol       Date:  2009-05-26       Impact factor: 9.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.